Orchestra BioMed presented late-breaking MODERATO II clinical data at the Heart Rhythm Society 2026 meeting in Chicago on April 25, with Prof. Karl-Heinz Kuck delivering six-month outcomes for AVIM Therapy — a bioelectronic hypertension treatment delivered through a standard dual-chamber pacemaker. The presentation, alongside Prof. Milan Chovanec’s pressure-volume analysis the prior day, is the strongest public data readout for AVIM since the FDA awarded it Breakthrough Device Designation in April 2025. It arrives as the Medtronic-partnered BACKBEAT global pivotal trial moves further into enrolment under an FDA-amended protocol that expanded the eligible patient population by more than 24-fold.
The platform-expansion mechanic — a therapy mode delivered through an already-approved device class, rather than a new device seeking its own clearance — is what makes AVIM consequential beyond the hypertension indication. AVIM rides on standard pacemaker hardware that has been implanted in millions of patients worldwide for arrhythmia indications. Orchestra BioMed’s regulatory submission is for a therapy delivered through that existing class, not for new silicon. The mechanic is the template every Medtronic, Abbott, and Boston Scientific portfolio strategist watches.
MODERATO II numbers
The randomised, prospective, multi-centre, double-blind, controlled MODERATO II trial produced a 12.3 mmHg net reduction in office systolic blood pressure at six months versus control, and an 8.1 mmHg net reduction in 24-hour ambulatory systolic blood pressure — the more rigorous endpoint, since ambulatory BP corrects for white-coat effect and captures real-world variability. The immediate-activation effect on office systolic BP was 13.2 mmHg, and 97 per cent of treated patients achieved at least a 5 mmHg office systolic reduction. By six months, 89 per cent of treated patients had ambulatory systolic BP under 140 mmHg, and 58 per cent under 130 mmHg. A subcohort has been followed for up to 3.6 years with sustained effect.
These are pharmaceutical-comparable numbers. A typical antihypertensive monotherapy delivers ambulatory systolic reductions of 5 to 10 mmHg. AVIM is competing directly with the pharmacotherapy outcomes envelope in a population that has by definition failed adequate medication control.
The Medtronic vector
Orchestra BioMed and Medtronic formed their strategic collaboration in July 2022 for the development and commercialisation of AVIM Therapy in pacemaker-indicated patients with uncontrolled hypertension. The partnership is structured around Medtronic’s pacemaker installed base and pipeline rather than around dedicated AVIM hardware. The mechanism — atrioventricular interval modulation, which reduces cardiac preload and effective arterial elastance independent of lead location and without affecting left ventricular contractility — is hardware-agnostic enough that it can in principle be deployed across multiple Medtronic pacemaker generations.
The commercial implication is that AVIM, on approval, would not require the lengthy specialty-implant infrastructure that has held up adoption of every other novel cardiac rhythm device. The implanting cardiologist already exists. The patient pathway already exists. The hardware reimbursement category already exists. What is being added is a software-governed therapy mode that switches on for the subset of pacemaker-indicated patients who also have uncontrolled hypertension — a population Orchestra BioMed estimates at over 7.7 million in the United States alone.
The bioelectronic widening
The AVIM precedent is the cleanest current example of bioelectronic medicine moving out of niche neural and arrhythmia applications into mainstream cardiometabolic disease. The same architectural move — software-defined therapy delivered through approved implant hardware, with a partnership-led commercial route through a major medtech incumbent — is the template that Galvani, Setpoint, LivaNova’s vagus-nerve programmes, and several Chinese players are pursuing in inflammation, metabolic disease, and heart failure. Orchestra BioMed is the most advanced public benchmark.
The BACKBEAT readout, when it arrives, will be one of the more consequential bioelectronic-medicine data events of the year. It will validate or complicate the platform thesis that an existing implant class can be repurposed to treat a non-electrical disease, and it will set expectations for the next wave of pacemaker-delivered, defibrillator-delivered, and neurostimulator-delivered software therapies.
The MODERATO II data confirms the signal. The pivotal trial’s amended protocol gives Orchestra BioMed and Medtronic the population they need. What remains is execution.